EGFR and lung adenocarcinoma: There was also a case report of a patient with stage III lung adenocarcinoma who developed primary-lesion progression and brain metastasis after first-line concurrent radiotherapy and immunotherapy, with genetic testing suggesting an EGFR T751_I759delinsS mutation and an EGFR amplification; this was followed by afatinib treatment, with shrinkage of both brain and chest lesions and 9 months of PFS [28].